Anzahl der Publikationen: 4
2022
Tilch, Marie-Kristin; Visco, Carlo; Kinda, Sandra; Hermine, Olivier; Kohn, Milena; Besson, Caroline; Lamure, Sylvain; Dulery, Remy; Ragaini, Simone; Eyre, Toby A.; Meerten, Tom van; Ohler, Anke; Eckerle, Steffen; Dreyling, Martin; Hess, Georg; Gine, Eva und da Silva, Maria Gomes
(2022):
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry.
In: Hemasphere, Bd. 6, Nr. 5, e0711
Rusconi, Chiara; Cheah, Chan Y.; Eyre, Toby A.; Tucker, David; Klener, Pavel; Gine, Eva; Crucitti, Lara; Muzi, Cristina; Iadecola, Sara; Infante, Gabriele; Bernard, Sophie; Auer, Rebecca L.; Pagani, Chiara; Duglosz-Danecka, Monika; Mocikova, Heidi; Meerten, Tom van; Cencini, Emanuele; Marin-Niebla, Ana; Williams, Michael E.; Angelillo, Piera; Nicoli, Paolo; Arcari, Annalisa; Morello, Lucia; Mannina, Donato; Vitagliano, Orsola; Sartori, Roberto; Chiappella, Annalisa; Sciarra, Roberta; Stefani, Piero M.; Dreyling, Martin; Seymour, John F. und Visco, Carlo
(2022):
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
In: Blood, Bd. 140, Nr. 17: S. 1907-1916
Eyre, Toby A.; Shah, Nirav N.; Dreyling, Martin; Jurczak, Wojciech; Wang, Yucai; Cheah, Chan Y.; Song, Yuqin; Gandhi, Mitul; Chay, Christopher; Sharman, Jeff; Andorsky, David J.; Messersmith, Hannah M.; Ruppert, Amy S.; Muthig, Valerie A.; Ito, Rodrigo und Wang, Michael L.
(2022):
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
In: Future Oncology, Bd. 18, Nr. 36: S. 3961-3969
2021
Collins, Graham P.; Eyre, Toby A.; Schmitz-Rohmer, Debora; Townsend, William; Popat, Rakesh; Giulino-Roth, Lisa; Fieds, Paul A.; Krasniqi, Fatime; Soussain, Carole; Sathis, Anastasios; Andjelkovic, Nebojsa; Cuniingham, David; Mandic, Danijela; Radulovic, Sinisa; Tijanic, Ivan; Horowitz, Netanel A.; Kurtovic, Sabira; Schorb, Elisabeth; Schmidt, Christian; Dimitrijevic, Sasa und Dreyling, Martin
(2021):
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
In: Hemasphere, Bd. 5, Nr. 11, e656
Diese Liste wurde am
Sat Dec 21 21:47:41 2024 CET
erstellt.